Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells

By W. Qasim, H. Zhan, S. Samarasinghe, S. Adams, P. Amrolia, S. Stafford, K. Butler, C. Rivat, Gary Wright, K. Somana and 15 more. Science Translational Medicine, 2017

836 citations recorded by the source corpus.

Subfields: Oncology

View Paper: https://www.semanticscholar.org/paper/55433abbe8a0a59e160cbe047a01e274182e2a19

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

Citations in the corpus

CRISPR-engineered T cells in patients with refractory cancer (2020, background): “In a subsequent clinical report using dual-gene editing with TALENs, chromosomal rearrangements were observed in 4% of infused cells (40).”
Gene therapy clinical trials worldwide to 2017: An update (2018, methodology): “Although long‐term follow up is still required, promising reports for gene‐editing technology are now appearing in the literature with a zinc finger nucleases used in a clinical trial for the treatment of HIV‐1(93) and a transcription activator‐like effector nuclease used to treat two children with ”
Gene therapy comes of age (2018, neutral): “These modified cells were administered to two patients with refractory B cell acute leukemia on a compassionate basis, with evidence for tumor response (74), and are in phase I clinical trials (NCT02808442).”
Engineering strategies to overcome the current roadblocks in CAR T cell therapy (2019, methodology): “Transcription activator-like (TAL) effector nuclease (TALEN) technologies have also been used to knockout the TCR 232 , and TALEN-edited anti-CD19 CAR T cells have induced remissions in infants with B cell ALL, with no GVHD observed 233 .”
CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment (2019, background): “The subsequent universal CAR T cells, which were from allogeneic donors, induced remission in two infants with B cell ALL (187).”
Therapeutic T cell engineering (2017, neutral): “4-1BB LV 29 CY/CF 1:14/8 93% Qasim, 2017 (ref.”
Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects (2020, background): “The beneficial role of TCRdepleted CD19 CAR T cells in evading GVHD has recently been validated in two infant patients with relapsed refractory CD19+ B cell acute lymphoblastic leukemia, leading to successful molecular remissions within 4 weeks.(225) In addition, the target of the lymphocytic deplet”